Stephanie J. Hachey

The paper introduces the ImmuniT platform, which improves neoantigen prediction in lung cancer by identifying more immunogenic targets than conventional methods.

This study identifies PHLDA2 as a driver of breast cancer metastasis by reactivating a placental vascular remodeling program through hypomethylation and SPARC-mediated effects.

This study identifies CDC42 inhibitors that reduce vessel branching in both normal skin and tumors, offering potential for treating skin cancer and angiogenesis-related diseases.

The paper presents an image processing pipeline for analyzing vascularized micro-organ and tumor systems using Fiji/ImageJ tools, reducing manual processing time and enabling real-time imaging insights.

The paper uses a vascularized micro-tumor model to identify therapeutic targets in TNBC stromal interactions, showing efficacy of Tie2 and Her3/Akt inhibition.

This paper designs a CDC42 effector interaction inhibitor (ARN22089) that shows anti-cancer activity by blocking tumor invasion and angiogenesis.